Clinical Trials Logo

Smoking Cessation clinical trials

View clinical trials related to Smoking Cessation.

Filter by:

NCT ID: NCT05031416 Not yet recruiting - Smoking Cessation Clinical Trials

Developing and Pilot Testing a Remote Smoking Cessation Digital Therapeutic for Individuals With Serious Mental Illness

Start date: November 2024
Phase: N/A
Study type: Interventional

This is a pilot randomized clinical trial testing an implementation intervention to support delivery of a smoking cessation app tailored to the needs of those individuals with SMI who at community mental health programs.

NCT ID: NCT04987268 Not yet recruiting - Smoking Cessation Clinical Trials

CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation

CHIP-RETENTION
Start date: August 20, 2021
Phase:
Study type: Observational [Patient Registry]

In order to identify the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS patients undergoing complete revascularization and perform whole-exome sequencing for enrolled patients to identify the prevalence of CHIP mutations. After 1-year follow-up, the relationship of presence of CHIP mutations and the occurrence of MACCEs will be explored, irrespective of smoking cessation or not. CHIP may be a potential risk factor of poor prognosis of ACS.

NCT ID: NCT04891939 Not yet recruiting - Smoking Cessation Clinical Trials

Development and Assessment of a Teacher-led Intervention in Preventing Tobacco Use Among the Youth in Ghana

Start date: June 2021
Phase: N/A
Study type: Interventional

The main purpose of this experimental study is to compare the existing health education program for School Health and Education Program (SHEP) in the Junior High Schools with a new health education model (Smart-Kids') for the prevention of smoking initiation and to improve the quit rate among students in Upper East Region of Ghana. The intervention will be based on the Theory of Triadic Influences (TTI) which involves the cultural environment in which adolescents mature, their immediate social situation, and intrapersonal differences. These three factors impact through different mediating variables, such as attitudes, normative beliefs, and self-efficacy, which eventually affect smoking intentions and smoking behavior as the outcome measures. The study design is a cluster randomized control trial. After baseline assessment, the investigators will randomize schools to receive the new health education for three months whiles the comparator (control group) will continue with the usual health education. The investigators will conduct a post-intervention assessment using the same questionnaire with unique identity codes linking each participant to their baseline assessments immediately at the end of the intervention. Final assessment will be done approximately three months after the intervention. The investigators will assess and compare the effectiveness of the new health model to the normal health promotion programs (SHEP). The investigators hypothesized that there will be no significant differences observed between the new teacher-led health education program (the Smart-Kids Program) and the existing SHEP coordinator-led in preventing smoking uptake among the youth. Alternatively, the new teacher-led health education program would facilitate the effects of the program on outcomes. on four key primary endpoints as follows: - H1: The intervention study will result in a 30% reduction in smoking uptake - H2: The intervention study will result in a 10% reduction in smokers - H3. The intervention will increase knowledge of the harmful effects of tobacco use by 50% - H4. The intervention will increase the willingness to quit smoking by 10% among smokers

NCT ID: NCT04843605 Not yet recruiting - Smoking Cessation Clinical Trials

Systematic Screening for COPD in Tabacology Consultation

DEBOTA
Start date: May 16, 2021
Phase:
Study type: Observational

COPD is a very common disease, an estimated 3 million people are affected in France. Unfortunately, this pathology is under-diagnosed. Several reasons can be mentioned: the banality of the symptoms or the several comorbidities. Screening faces a major difficulty: the realization of a spirometry. Various studies have shown the complexity of the implementation of mass screening in cities by mini-spirometry. The COPD World Health Days allow this mass screening but without visibility on the actual entry into a care pathway. The objective of this study is to assess the impact of systematic screening for COPD during a tabacology consultation

NCT ID: NCT04630340 Not yet recruiting - Smoking Cessation Clinical Trials

An Innovation to Increase Smoking Quit Rate

STEADES-2
Start date: January 2021
Phase: N/A
Study type: Interventional

An Innovation involving Self-Surveillance and Serious Gaming to Increase Smoking Quit rate: Protocol for a randomized controlled trial. Abstract Introduction and study aims Smoking is a health hazard associated with cancer, vascular and lung diseases. Current methods to manage smoking cessation have limited success. A recent systematic review suggests increase in smoking cessation potential via serious gaming to attain desirable healthcare outcomes. Outcomes are limited in these studies to demonstrate, quantify, and understand these interventions. The investigators have demonstrated feasibility of a portable device ("STEADES-1") which allows smokers to measure their exhaled-breath carbon monoxide (eCO) levels, related to their cigarette-smoking intensities. They can relay the eCO measurements via smart-phone applications (app) to their virtual coach to report their smoking cessation progress. The investigators have created an enhanced STEADES-2 system, which incorporates gamification using the eCO data as game element and allows anonymized smokers to compete with each other for the game rewards. It has additional authentication functions and embeds an e-coaching program by trained healthcare professionals. Methods and analysis This pilot randomized controlled trial aims to evaluate the feasibility and outcomes of the STEADES-2 system in increasing smoking quit rate. The former includes assessing the smokers to monitor their eCO levels; leverage on telesupport via the e-Coaching to raise their motivation; reduce relapse tendencies by playing serious games with fellow smokers. The investigators postulate that the smoking quit rate in smokers in the STEADES-2 intervention group will be higher by 50% than the controls over 12 weeks. This trial will randomly select 20 smokers each into the intervention group and the control group. Smokers in both groups will be compared in terms of complete abstinence from cigarettes as the primary outcome at 12 weeks post-enrolment. Ethics and dissemination The Institutional Review Board approves the study. The results will be disseminated via conferences and publications.

NCT ID: NCT04190966 Not yet recruiting - Smoking Cessation Clinical Trials

Smoking Cessation in the Surgical Pathway Before Major Lung Surgery

MURRAY
Start date: January 31, 2020
Phase: N/A
Study type: Interventional

This is a feasibility study of a personalised, integrated smoking cessation in the surgical pathway in patients undergoing major elective thoracic surgery when compared to usual care of standard community/hospital based NHS smoking cessation. Half the patients will receive the intervention and half the patients will receive usual care.

NCT ID: NCT04007549 Not yet recruiting - Breast Cancer Clinical Trials

Brief Intervention for Tobacco and Alcohol Risk Reduction for Couple During Breast Cancer Treatment.

IBMC
Start date: August 2019
Phase: Phase 3
Study type: Interventional

This study will examine the benefits of involving partner in a Screening, Brief Intervention and Referral to Treatment (SBIRT) program for tobacco and alcohol for women treated for breast cancer. Using a two-arm randomized trial (couple brief motivational intervention (CBMI) versus individual brief motivational intervention (IBMI) with repeated measures at 6 weeks, 3 and 6 months.

NCT ID: NCT03994445 Not yet recruiting - Smoking Cessation Clinical Trials

Effectiveness of Mobile Phone-Based Intervention to Prevent Smoking Relapse Among Recent Smoking Quitters

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Main Objective The main objective of the study is to investigate the effectiveness of a mobile phone-based intervention in reducing relapse ate among recent quitters who are attending the smoking cessation program in Jazan. Besides this, the study will achieve the following objective: To identify the timing and different factors associated with relapse process among recent quitters during first 6 months of quitting.

NCT ID: NCT03608852 Not yet recruiting - Smoking Cessation Clinical Trials

Unconventional Financial Incentives for Smoking Cessation

Start date: August 1, 2018
Phase:
Study type: Observational

The proposed study is a randomized study of actively smoking veterans cared for at the Miami VA Medical Center. Subjects are randomized into 2 groups and will all receive a regimen of nicotine replacement therapy (NRT) standardized to their smoking habit. Subjects are followed biweekly for smoking cessation by using biochemical tests (exCO and COHb) to determine smoking abstinence. The first group called the Banked-Money Group will have $50 placed in a 'bank account' for every clinic visit where their tests reveal abstinence from smoking. As a modified commitment contract, the Banked-Money Group can only withdraw the accrued money at the end of the trial if they complete the trial by quitting smoking for the entire 6 months. The second group called the Reward Group will directly receive $50 for every clinic visit where their tests reveal abstinence from smoking.

NCT ID: NCT03450941 Not yet recruiting - Smoking Cessation Clinical Trials

AXS-05 Phase II Trial on Smoking Behavior

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.